Phosphoinositide 3-kinase (PI3K)/protein kinase B/Akt and Ras/mitogen-activated protein kinase pathways are often constitutively activated in melanoma and have thus been considered as promising drug targets. Exposure of melanoma cells to NVP-BAG956, NVP-BBD130, and NVP-BEZ235, a series of novel, potent, and stable dual PI3K/ mammalian target of rapamycin (mTOR) inhibitors, resulted in complete G1 growth arrest, reduction of cyclin D1, and increased levels of p27 KIP1 , but negligible apoptosis. In contrast, treatment of melanoma with the pan-class I PI3K inhibitor ZSTK474 or the mTORC1 inhibitor rapamycin resulted only in minor reduction of cell proliferation. In a syngeneic B16 mouse melanoma tumor model, orally administered NVP-BBD130 and NVP-BEZ235 efficiently attenuated tumor growth at primary and lymph node metastatic sites with no obvious toxicity. Metastatic melanoma in inhibitor-treated mice displayed reduced numbers of proliferating and significantly smaller tumor cells. In addition, neovascularization was blocked and tumoral necrosis increased when compared with vehicle-treated mice. In conclusion, compounds targeting PI3K and mTOR simultaneously were advantageous to attenuate melanoma growth and they develop their potential by targeting tumor growth directly, and indirectly via their interference with angiogenesis. Based on the above results, NVP-BEZ235, which has entered phase I/II clinical trials in patients with advanced solid tumors, has a potential in metastatic melanoma therapy. (Mol Cancer Res 2009;7(4):601-13) 
Introduction
Cancer cells evolve from a benign, noninvasive state to metastatic tumors, which grow and proliferate aggressively and display diminished cell death out of their normal tissue context. This process is driven by the accumulation of genetic and epigenetic alterations (1) , which leads to sustained inputs into multiple signal transduction pathways. Activation of phosphoinositide 3-kinase (PI3K) is a prominent relay to tumor growth as it promotes increase in cell mass and cell cycle entry, counteracts apoptosis, modulates cytoskeletal rearrangements, and enhances cell migration (2) (3) (4) .
Excess growth factor expression, constitutively activated protein tyrosine kinase receptors (e.g., epidermal growth factor receptor, c-kit, platelet-derived growth factor receptor, Met), oncogenic Ras, loss of phosphatase and tensin homologue deleted in chromosome 10 (PTEN), and mutated PI3K can lead to an increase in the levels of the PI3K product PtdIns(3,4,5) P 3 . The latter serves as a docking site for pleckstrin homology domain-containing proteins such as protein kinase B (PKB/ Akt) and guanine nucleotide exchange factors feeding into growth and metastasis (3, 5) . A major output of PKB/Akt activation is the phosphorylation of tuberin in the tuberous sclerosis complex (TSC1/2), which releases the TSC1/ 2→Rheb→mammalian target of rapamycin (mTOR) pathway and leads to increased translation and transcription (6) .
Metastatic melanoma is a tumor with an exceptionally bad prognosis. Melanoma display already at early stages often mutated B-Raf (V600E; 66%) or constitutively activated N-Ras (mutation Q61K/L/R, 20%). An increase in tumor aggressiveness is observed in metastatic melanoma, which often correlates with the loss of PTEN (up to 60%) or up-regulation of PKBγ/ Akt3 (43-67%). Mutations of PI3K itself, as observed in other tumors for PI3Kα (PIK3CA; ref. 7) , are rare in cutaneous melanoma (8, 9) ; however, the PI3Kα protein was found to be upregulated (10) . Occasional mutations found in STK11/LKB1 (11) could also contribute to the activation of mTOR independent from PI3K in melanoma. Therefore, the Ras/mitogenactivated protein kinase (MAPK) and PI3K/mTOR signaling pathways were proposed as promising drug targets for the treatment of advanced melanoma (12) .
Clinical trials targeting the MAPK pathway (single therapy with the B-Raf inhibitor sorafenib/Nexavar/BAY 43-9006; ref. 13 ) did not yield significant success in melanoma despite beneficial effects of sorafenib in the treatment of renal cell carcinoma (14) . Now sorafenib is in clinical trials in combination with bevacizumab (Avastin), and other Raf inhibitors also entered clinical trials (PLX4032, Plexxikon; Raf265, Novartis). Trials with rapamycin derivatives targeting mTOR (CCI-779/temsirolimus, Wyeth) in melanoma had to be concluded too due to inefficacy (15) . New clinical trials targeting Raf and mTOR simultaneously have been initiated recently. 4 In preclinical models, the PI3K pathway was initially targeted with LY294002, a PI3K inhibitor with low potency, low specificity, and high toxicity (16) . LY294002 and wortmannin inhibit the whole PI3K family and related proteins, including mTOR, PI4K, DNA-PK (17) , and Polo-like kinases (18) . Improvements in PI3K inhibitor potency and selectivity were made with the pyridofuropyrimidine PI103 (19) (20) (21) , and, recently, the first orally administered pan-PI3K inhibitor ZSTK474 was presented (22, 23) .
Here, we report for the first time in melanoma the action of PI3K/mTOR inhibitors with drug-like properties, including NVP-BEZ235, which has entered phase I/II clinical studies for patients with advanced solid malignancies. Our results reported herein provide a basis for the evaluation and rational of action of PI3K pathway targeting in solid tumors and document a significant efficiency and insignificant adverse effects of the compounds used.
Results

Dual PI3K/mTOR Inhibitors Block Proliferation of Melanoma Cells
Melanoma cells often show constitutive activation of the PI3K pathway due to mutations and attenuation of the phosphatase PTEN or changes in PKBγ expression. Here, a collection of human melanoma cell lines generated from different tumor stages and three mouse melanoma lines of the B16 family were used to investigate the susceptibility of melanoma to PI3K pathway inhibition. Currently, the effect of PI3K inhibition on cell proliferation is controversial (12, 22, (24) (25) (26) (27) ; therefore, we first reevaluated the effect of the classic PI3K inhibitors wortmannin and LY294002. When cells were exposed to a single dose of inhibitor for 3 days, wortmannin was ineffective due to its limited stability ( Fig. 1A and B) . A set of newly identified, ATP-competitive PI3K/mTOR inhibitors, NVP-BAG956, NVP-BBD130, and NVP-BEZ235 (see Table 1 ; Supplementary Fig. S1 ; refs. 28, 29) , showed a long-term effect on melanoma cell proliferation, superior to even much elevated concentrations of LY294002 ( Fig. 1A and B) . NVP compounds prevented growth (<20% of normal growth) in >85% of the tested melanoma lines, independent of the status of PTEN and BRaf (Supplementary  Table S1 ) or the tumor stage the cells were derived from. The arrest in proliferation correlated with a reduction in cellular and nuclear size (data not shown). Interestingly, inhibitor-treated cells were able to reenter proliferation at a reduced rate and to gain normal cell volume when NVP-BAG956 and NVP-BEZ235 were removed, whereas cells exposed to NVP-BBD130 were arrested for up to 10 days and remained small (7 days in the absence of inhibitor; see Supplementary Fig. S2 ). Although in prolonged stasis, no significant cell death was observed.
To understand the mode of action of these novel compounds, we performed time course-and concentration-dependent experiments using malignant, aggressively growing cell lines, such as A2058, which have constitutively activated PI3K/PKB/Akt (Fig. 1C) and MAPK pathways (see Supplementary Fig. S3 ).
All used PI3K inhibitors decreased phosphorylation of PKB/ Akt, whereas the phosphorylation status of MAPK was not affected. The effect of wortmannin was short lived; levels of phosphorylated PKB/Akt were back to normal 2 to 4 hours after treatment. In the case of LY294002, the PKB/Akt phosphorylation was restored after 1 day. In contrast, a single addition of NVP compounds caused very prominent and prolonged dephosphorylation of PKB/Akt, even in melanoma showing PI3K inhibitor-resistant proliferation (e.g., C32; see Fig. 1A and C) . The potency of the three novel inhibitors to block phosphorylation of PKB/Akt in A2058 cells was in the nmol/L range (IC 50 value for NVP-BBD130 was 11 ± 4.6 nmol/L, for NVP-BEZ235 18 ± 6.4 nmol/L, and for NVP-BAG956 67 ± 25 nmol/L; Fig. 1D ). In addition, inhibition of PKB/Akt phosphorylation correlated with loss of A2058 cell proliferation for NVP-BBD130 and NVP-BEZ235 (IC 50 for NVP-BBD130 was 34 ± 2.6 nmol/L and for NVP-BEZ235 was 26 ± 2.5 nmol/L), whereas more of NVP-BAG956 was required to hinder proliferation (IC 50 was 290 ± 20 nmol/L; see Fig. 1E ). Altogether, when compared with the established compounds, the novel inhibitors exert prolonged action with superior stability in complex medium.
G1 Cell Cycle Arrest of Melanoma Cells Upon Treatment with PI3K/mTOR Inhibitors
The effect of PI3K inhibitors on the cell cycle is shown here in detail for A2058 melanoma cells ( Fig. 2 ; more melanoma lines in Supplementary Table S2) : Melanoma treated with wortmannin and LY294002 showed no significant shifts in cell cycle profiles compared with nontreated cells, whereas PC3M cells, which are very sensitive to PI3K inhibitors (Supplementary Fig. S4A ; refs. [30] [31] [32] , displayed a prominent cell cycle arrest in G1 with LY294002. NVP-BAG956, NVP-BBD130, and NVP-BEZ235 resulted in a complete arrest of most tumor cells in G1, which correlated with a lack of proliferation and DNA replication (as measured by [ 3 H]thymidine incorporation; Fig. 2B ). PI3K inhibitor-resistant proliferation was observed in C32 melanomas, which consequently also showed no G1 arrest ( Fig. 1A ; Supplementary Table S2) . Moreover, PI3K inhibition did not induce evident signs of apoptosis as monitored by the absence of sub-G1 peaks ( Fig. 2A and data not shown) and Annexin V-positive cells (Supplementary Fig. S4B ; Supplementary Table S2 ). PI3K/mTOR inhibitors thus have cytostatic, but no cytotoxic, effects on melanoma cells.
Cell cycle progression is regulated by the oscillating expression of cyclins and the inhibition of specific cyclin/cyclindependent kinase (Cdk) complexes by Cdk inhibitors. Expression of cyclin D1 is down-regulated in A2058 cells treated with NVP compounds and is somewhat reduced by treatment with LY294002 (Fig. 2C) . A minor decrease in cyclin D1 was observed in control and wortmannin-treated cells, as they reached confluence at later stages. In inhibitor-resistant C32 cells, PI3K/ mTOR inhibition caused compound-dependent elevations in cyclin D1 levels (Fig. 2C) . Similarly, p27
Kip1 expression was clearly induced by NVP-BAG956, NVP-BBD130, and NVP-BEZ235 in A2058 cells but not in C32 cells.
To investigate stringency and rapidity of the cell cycle arrest in G1 induced by PI3K pathway inhibition, A2058 cells were synchronized with the microtubule disruptor nocodazole in G2-M and released subsequently in the presence of vehicle or PI3K inhibitors: (a) the initial treatment with nocodazole arrested cells in G2-M (from 30% to 60% of cells in G2-M; Fig. 2D ); (b) after nocodazole removal, control and wortmannin-treated cells showed a profile typical of proliferating cells after 24 h, whereas cells exposed to LY294002 required 48 h to restart proliferation. In the presence of NVP-BAG956, NVP-BBD130, or NVP-BEZ235, A2058 cells were only able to exit G2-M and then remained in G1 (Fig. 2D ).
Primary and Metastatic Tumors Require the PI3K Pathway for Growth In vivo
To evaluate the efficacy of different PI3K/mTOR inhibitors in vivo, we used a syngeneic B16BL6 mouse melanoma model, in which cells, injected intradermally in both ears, rapidly progress to primary tumors and cervical lymph node metastasis. Treatment with vehicle control, PI3K/mTOR inhibitors, and a vascular endothelial growth factor receptor (VEGFR) protein tyrosine kinase inhibitor (PTK787) were started 7 days following tumor inoculation. A ∼60% reduction in the primary tumor size was achieved with different doses and regimens of NVP-BBD130, NVP-BEZ235 and PI103 (Fig. 3A) , and PTK787 (data not shown). Moreover, mice treated with NVP-BBD130, NVP-BEZ235, or PTK787 showed a significant reduction in the size of the cervical lymph node metastasis ( Fig. 3B ; PTK787: data not shown). For NVP-BBD130, tumor and metastasis size reduction correlated with a stringent reduction in the amount of phosphorylated PKB/Akt and p70 S6K 2 hours after the last treatment (Fig. 4A) . A partial recovery to basal level was seen after 16 hours. In addition, reduced expression of cyclin D1 and increased levels of p27 Kip1 were detected in metastatic tissue 2 hours after dosing (Fig. 4B) . Intriguingly, treatment with PI103 at the concentration used here did not significantly reduce the mass of lymph node metastasis (Fig. 3B) , which was in agreement with overshooting signals for phosphorylated PKB/Akt and p70 S6K in primary and metastatic tumor tissue (Fig. 4A) . As PI103 is cleared rapidly from the tumor (half life <2 hours; see ref. 20) , these elevated and dose-dependent signals could represent a release of feedback loops in the PI3K/mTOR signaling system.
A closer analysis of metastatic sections revealed that cell size was decreased in tumor tissue from inhibitor-treated animals (Fig. 5A ), but not in hepatocytes of the same mice. This is encouraging, as liver cell size dynamically responds to starvation and the current PI3K/mTOR treatment regimen seems not to fully mimic nutrient deprivation. Plasma levels of liver marker enzymes and proteins were also not significantly affected by the treatment with PI3K/mTOR inhibitors (except alanine aminotransferase; see Supplementary Table S3) . Interestingly, PI3K inhibitor-mediated reduction in cell size went along with a decreased mitotic index (Fig. 5B ). The few remaining mitotic cells were usually located around preexisting, large blood vessels. In addition to reduced cell proliferation, metastatic tissue from mice treated with NVP-BEZ235 displayed significantly increased necrosis levels compared with tumors from vehicle control-treated mice (Fig. 5C ).
To survive and grow, tumors with a diameter larger than 1 mm require blood vessels to be fully supplied with nutrients and oxygen. Staining of metastatic sections for the endothelial cell marker CD31 revealed that NVP-BBD130 and NVP-BEZ235 completely abrogated neoangiogenesis in metastatic tissue, whereas vehicle control-, PI103-, or PTK787-treated tumors displayed a well-developed microvasculature ( Fig. 6A ; quantification in Fig. 6B ). Large and preexisting blood vessels at the tumor border remained unaffected by all treatments (data not shown). Altogether, the above results show that the novel NVP compounds have a direct effect on tumor cell growth and proliferation, and exert, in addition, antiangiogenic effects supporting tumor necrosis.
PI3K/mTOR Inhibitors Are Well Tolerated
Tumor-bearing mice showed a disease-related drop in body weight by 5% to 10% and had >2-fold enlarged spleens when compared with healthy controls (Table 2 ). PI3K inhibitor-treated animals showed a less dramatic increase in spleen size and an overall tendency to regain body weight, reaching significance for PTK787 and NVP-BEZ235 (data not shown). The collected data illustrate that the tumor per se causes dramatic systemic changes, which were partially reversed by PI3K/mTOR inhibition. Interference with insulin-mediated glucose uptake also seemed negligible, as blood glucose levels did not significantly increase over concentrations determined in healthy and vehicle control-treated animals ( Table 2) .
PI3K and mTOR have been reported to play important roles in the immune system. Spleen and bone marrow of NVP-BBD130-and PI103-treated mice were therefore analyzed for adverse effects on immune cells. Tumor-bearing, vehicle control-treated mice displayed a reduction in the number of CD3 + T cells, B cells, and natural killer cells, compared with healthy animals (Supplementary Table S4 ), and NVP-BBD130 treatment decreased lymphocyte counts in a statistically insignificant manner. Interestingly, treatment with PI103 resulted in an increase in the number of T cells, B cells, and natural killer cells back to levels similar to healthy control animals. Granulocytes, macrophages, and erythroid cell numbers were normal in the bone marrow of all tumor-bearing mice, and there was no indication that the applied PI3K/mTOR inhibitors interfered with hematopoiesis.
Cooperation of PI3K and mTOR in Melanoma Cell Proliferation
To discriminate between the importance of PI3K and mTOR, we ectopically expressed a constitutively active PKB/ Akt (myristoylated PKB, Myr-PKB; ref. 33 ) to partially bypass the inhibitor-mediated block in PI3K signaling. To monitor PKB/Akt action, we used the mTOR-independent nuclear to cytoplasmic translocation of forkhead transcription factors (FOXO), which feed negatively into cell cycle progression and antiapoptotic events (34, 35) . Nonphosphorylated FOXOs are localized to the nucleus but are retained in the cytoplasm when phosphorylated by PKB/Akt. In A2058 cells, PKB/Akt is maintained activated in a PI3K-dependent manner even in serum-free conditions, mainly due to the lack of the lipid phosphatase PTEN. As a consequence, ectopically expressed FOXO1 is quantitatively localized in the cytoplasm. Treatment of A2058 cells with NVP compounds caused a rapid inactivation of PKB/Akt and a subsequent translocation of FOXO1 to the nucleus (Fig. 7A ). Stable expression of Myr-PKB in A2058 was sufficient to prevent nuclear translocation of exogenous FOXO1 in the presence of PI3K inhibitors, but did not rescue proliferation in the presence of, e.g., NVP-BEZ235 (Fig. 7B) .
In serum-deprived HEK293 cells, Myr-PKB reconstituted phosphorylation of FOXO and GSK3β and also fed into mTOR signaling with phosphorylated p70 S6K , S6, and 4E-BP1 as readouts ( Supplementary Fig. S5 ). Whereas FOXO and GSK-3β phosphorylation was to a large extent PI3K inhibitor resistant, signals downstream of mTOR were completely abrogated by NVP-BAG956, NVP-BBD130, NVP-BEZ235, and PI103, as well as by the mTORC1 inhibitor rapamycin. This corroborates mTOR inhibition by NVP compounds observed in TSC1 knockout mouse embryonic fibroblasts (Table 1; see ref. 28) .
Recently, a selective pan-PI3K inhibitor without activity against mTOR (ZSTK474) was shown to block tumor cell growth with an overall 50% sensitivity rate (22, 23) . To evaluate the requirement of a dual PI3K and mTOR inhibition to target melanoma, cells were comparatively exposed to NVP-BEZ235, ZSTK474, and/or rapamycin. The obtained results clearly illustrate that targeting either PI3K or mTOR in isolation can attenuate growth and proliferation of particularly sensitive cells (e.g., A375), whereas more resistant melanoma are only affected by the simultaneous targeting of PI3K and mTOR (Fig. 8A) . Treatment of melanoma cells with a combination of ZSTK474 and rapamycin results in a more pronounced proliferation arrest compared with single compounds. The were exposed to the indicated inhibitors (LY294002 at 25 μmol/L; wortmannin at 500 nmol/L; NVP-BAG956, NVP-BBD130, and NVP-BEZ235 at 1 μmol/L) for 3 d before cell numbers were determined. Cell numbers are depicted after the subtraction of initially seeded cells in relation to nontreated controls (ratio of treated over nontreated cultures). Columns, mean of triplicates; bars, SE. B. Time-dependent A2058 proliferation in the presence of PI3K inhibitors. A2058 cells were exposed to PI3K inhibitors at day 0 before cells were counted at the indicated time intervals. Points, mean of triplicates; bars, SE. C. Prolonged changes in phosphorylation of PKB/Akt upon PI3K inhibition. Phosphorylated PKB as detected in total cell lysates of A2058 and C32 cells treated with PI3K inhibitors for the indicated intervals are shown. An extended version of the figure is presented in Supplementary Fig. S3 . D. Concentration-dependent inhibition of PKB phosphorylation. A2058 cells were exposed for 3 h to increasing concentrations of NVP-BAG956, NVP-BBD130, and NVP-BEZ235. Total cell lysates were subjected to immunoblotting for total and phosphorylated PKB or MAPK. Emerging signals were quantified using fluorescent secondary antibodies, and ratios of phosphosphorylated over nonphosphorylated kinases are displayed. Points, mean (n > 3); bars, SE. E. Inhibitory activity of PI3K inhibitors against melanoma cell proliferation. A2058 cells were treated at day 0 with increasing concentrations of NVP-BAG956, NVP-BBD130, and NVP-BEZ235. Cell proliferation was evaluated 3 d later. Points, mean of triplicates; bars, SE.
differential modulation of the phosphorylation status of PKB and p70
S6K by the various inhibitors in sensitive and more resistant cell lines shows that the degree of the coupling of PI3K to mTOR varies, and a retained activation of mTOR in the presence of PI3K inhibitor (as, e.g., in 1205lu cells; Fig.  8B ) requires an efficient PI3K/mTOR dual-mode inhibitor to attenuate growth.
Discussion
The recognition that the PI3K pathway has gained as a putative target in cancer therapy (2-4) is reflected by a recent increase in patent literature covering novel PI3K inhibitors (36, 37) and documents the need for compounds with improved stability, efficacy, and potency. The newly developed series of ATP-competitive PI3K/mTOR inhibitors (28, 29) , NVP-BAG956, NVP-BBD130, and NVP-BEZ235, fit these criteria, and NVP-BEZ235 has recently entered clinical trials. NVP-BEZ235 (28) and NVP-BBD130 ( Supplementary Fig. S6 ) have advantageous pharmacologic profiles and show a high and sustained exposure in tumor tissue in vivo. Neither their effects in aggressive, metastatic tumors in syngeneic models nor the requirement of a dual inhibition of PI3K and mTOR was studied thus far.
Incubation of asynchronously growing melanoma cells with NVP compounds resulted in a complete loss of PKB/Akt phosphorylation and induced growth arrest, but not apoptosis, which is in agreement with earlier reports for PI3K pathway inhibitors (12, 22, 26) . The observed growth arrest was dose dependent and correlated with the loss of phosphorylation of PKB/Akt. Cells accumulated in the G1 cell cycle phase showing upregulation of the cell cycle inhibitor p27 Kip1 , reduction in cyclin D1 levels, and a complete block of DNA synthesis. In all cell lines tested here, the effect of NVP compounds on cell proliferation was superior and prolonged when compared with the action of LY294002 and wortmannin. A small fraction of the cells tested responded only partially to PI3K/mTOR inhibition and consequently did not show a G1 arrest or changes in p27 Kip1 . Increased cellular cyclin D1 has been previously associated with poor prognosis in many cancers and has also been reported to correlate with B-Raf inhibitor resistance in melanoma (38) . Further studies will be required to determine if the inhibitor-induced increase in cyclin D1 levels depicted in C32 cells confers resistance to PI3K/mTOR inhibition in a general sense. Similarly, the low expression or mutation of the lipid phosphatase PTEN, a constitutive activation of the PI3K pathway, the presence of mutated Ras or Raf, or the p53 status cannot be currently translated into a reliable pattern to predict sensitivity of melanoma to PI3K/mTOR inhibition.
To assess the in vivo activity of NVP-BBD130 and NVP-BEZ235, a B16 melanoma model was used: This syngeneic mouse model allows the evaluation of pharmacologic effects on the progress of an aggressive primary tumor and the precise quantification of a secondary metastatic lymph node tumor. Moreover, other than in xenograft models, mice have here an intact immune system and the effects of drugs on immune cell counts can be monitored. This is important as melanoma patients mount spontaneous T cell-dependent responses against their tumor, which correlate with patient survival (39) . One might thus anticipate that optimal treatment should not interfere with antitumoral immune responses.
NVP-BBD130 and NVP-BEZ235 could be administered orally and have excellent pharmacologic properties, whereas PI103 required i.p. application. Treatment of mice with different doses and regimens of inhibitors resulted in a ∼60% reduction of the primary tumors independently of the inhibitor used. Size of lymph node metastasis was also greatly reduced in mice treated with NVP-BBD130 and NVP-BEZ235, whereas treatment with PI103 (10 mg/kg/d) had insignificant effects on the mass of metastasis. In a first report, Fan et al. (19) obtained an antitumoral activity of PI103 in glioma xenografts with doses as low as 5 mg/kg/d. In contrast, Raynaud et al. (20) used the same glioma tumor model and achieved comparable results only at 100 mg/kg/d and recently Chen et al. (21) showed that PI103 at 10 mg/kg/d was not efficacious as a single agent in a different glioblastoma model. In the melanoma model used here, a dose of 10 mg/kg/d of PI103 was sufficient to attenuate primary tumor growth as observed for NVP-BEZ235, whereas a significant reduction in lymph node metastasis could not be detected. It is tempting to explain the lack of action on the lymph node metastasis by a restricted access of PI103 to metastatic tumor tissue. This is, however, challenged by the observation that increasing doses of PI103 caused a dose-dependent, paradoxical increase in phosphorylated PKB/Akt and p70 S6K in both the primary tumor and the metastasis in cervical lymph nodes. As Ser473 on PKB/Akt is mainly phosphorylated by TORC2 (40) in the absence of DNA damage (41, 42) , and Thr389 phosphorylation on p70 S6K is mediated by TORC1, these phosphorylation patterns suggest that both mTOR complexes are in an overactivated state 2 hours after the last PI103 administration in a prolonged treatment scheme. As PI103 was used here at low doses and has a short half life (<2 hours; ref. 20) , these results indicate that PI3K/mTOR signaling overshoots after a transient inhibition. BBD130, maintaining exposure to the tumor for a prolonged time (16 h/nmol/g), shows a clear reduction of Ser473 phosphorylation on PKB/Akt and Thr389 on p70 S6K until 16 hours after administration. The above result suggests that inhibitor half-life, exposure, and dosage frequency might affect the success of PI3K/mTOR modulation, and that phospho-PKB/Akt and phospho-p70 S6K need validation as biomarkers in conjunction with given compounds.
A close examination of melanoma tissue from mice treated with NVP-BBD130 and NVP-BEZ235 revealed that the mitotic index of metastatic cells in the cervical lymph nodes were reduced to more than half of untreated controls. This went along with a reduction in tumor cell mass, whereas cell size in other organs like the liver remained unaffected. The liver adapts to starvation by a reduction in cell size (43) . As current PI3K/ mTOR inhibitor treatments did not affect normal liver morphology, one may assume that nutrient uptake was functional. NVP-BBD130 at high single dose (40 mg/kg) showed a significant increase of the liver alanine aminotransferase in the plasma, which correlates with the increased liver retention of BBD130 compared with BEZ235 (Supplementary Fig. S6; ref. 28 ). Splitting the daily dose of NVP-BBD130 (2 × 20 mg/kg) reduced the A2058 melanoma cells were exposed to PI3K inhibitors for 3 d. Subsequently, the cell cycle profile was evaluated by fluorescence-activated cell sorting using propidium iodide staining. For more cell lines, see Supplementary Table S2 . *, P < 0.002. B. PI3K and DNA replication. release of alanine aminotransferase. Moreover, we could not detect significant differences in blood glucose levels between inhibitor-treated and vehicle control mice, showing that the inhibition of the PI3Ks is not impairing the glucose homeostasis.
Angiogenesis is required for nutrient supply and growth of tumors beyond 1 mm (44) and has been shown to be sensitive to mTOR inhibition by rapamycin and its derivatives (45, 46) . Supporting this notion, tumors excised from NVP-BBD130-and NVP-BEZ235-treated mice displayed a significant reduction in neovascularization, whereas large, preexisting blood vessels were not affected by targeting PI3K and mTOR. Intriguingly, mice treated with PI103 or the VEGFR inhibitor PTK787 showed no significant reduction in the amount of new blood vessels compared with vehicle control mice. Whereas NVP-BEZ235 and NVP-BBD130 are very potent PI3K and mTOR inhibitors, their effect on the VEGF receptor tyrosine kinase activity is negligible (IC 50 for VEGFR1 >10 μmol/L). Despite this fact, they blocked the formation of new blood vessels more efficiently than PTK787. The PI3K/mTOR signaling pathway has been reported to control the expression of HIF-1 via activation of p70 S6K and HDM2/MDM2. HIF-1 is the major regulator of VEGF transcriptional activity (47) . Feedback loops from mTOR to PKB/Akt and PI3K activation have been reported (48) , and also hypoxia-induced angiogenesis might require mTORC1 and mTORC2 (49) . Therefore, NVP-BBD130 and NVP-BEZ235 interfere with VEGFR ligand production and VEGFR downstream signaling to block blood vessel formation and exert at the same time cytostatic effects on tumor cells. This dual action could explain the higher efficiency of NVP-BBD130 and NVP-BEZ235 compared with PTK787, an inhibitor more selectively targeting endothelial cells through VEGFR inhibition. The effect of NVP-BBD130 and NVP-BEZ235 on neovascularization seemed to be crucial, as we noticed that tumor cells located in the vicinity of preexisting, large blood vessels still had some capacity to enter mitosis and displayed a nearly normal cell size (data not shown). It is therefore likely that the increased amount of necrotic tumor tissue observed in NVP-BEZ235-treated animals is caused by the very stringent targeting of neovascularization.
Our results indicate that the novel series of PI3K/TOR inhibitors attacks tumor progression by several molecular and physiologic mechanisms. To explore if the inhibition of mTOR in addition to PI3K is essential for blockage of tumor cell growth, we reintroduced constitutive PKB/Akt signaling in inhibitortreated cells. When activated, PKB/Akt modulates directly and indirectly a range of transcription factors, among them the FOXOs. Here, NVP compounds abolished phosphorylation of FOXO1 by PKB/Akt, thus abrogating its binding to 14.3.3 proteins, which resulted in a translocation to the nucleus. Ectopic expression of constitutively active PKB/Akt (myr-PKB) yielded a PI3K inhibitor-resistant, cytosolic retention of FOXO1, but was unable to bypass the cell cycle arrest imposed by NVP compounds. This could be due to the fact that signals downstream of mTOR (p70 S6K , S6, and 4E-BP1 phosphorylation) remained inhibitor sensitive in the presence of constitutively active PKB/Akt.
Melanoma cells displayed a <50% drop in the rate of proliferation after high doses of rapamycin (mTOR inhibitor, 100 nmol/L) or <25% after ZSTK474 (pan-PI3K inhibitor, 1 μmol/L) treatment. NVP-BEZ235 is a pan-PI3K inhibitor but also blocks mTOR, targeting the ATP-binding site of TORC1 and TORC2 (28) . Only the treatment of melanoma cells with dual inhibitors resulted in an efficient cytostatic, and in some rare cases cytotoxic, effect. The combination of rapamycin and ZSTK474 was more effective than either compound alone (<60%), but less effective than BEZ235. Whereas ZSTK474 inhibits class I PI3Ks, but not mTOR, rapamycin targets exclusively TORC1. Therefore, mTORC1 and simultaneously mTORC2 inhibition seems to be an important feature of NVP-BBD130 and NVP-BEZ235 action, which in combination with PI3K inhibition efficiently interferes with tumor growth in vivo.
In conclusion, inhibition of the PI3K/mTOR pathway via the nmol/L dual PI3K/mTOR inhibitors NVP-BBD130 and NVP-BEZ235 efficiently attenuates growth and proliferation of melanoma primary tumors and metastasis. Moreover, these compounds efficiently target neovascularization, and NVP-BEZ235 augmented tumor necrosis. In all, the above results encourage clinical development of this compound series and the inclusion of patients with melanoma in ongoing phase I/II studies involving NVP-BEZ235.
Materials and Methods
Cell Culture
Melanoma cells were grown at 37°C in a 5% CO 2 atmosphere in DMEM (A2058, B16F1, B16F10, C32, HBL, Malme, Malme3M, NA8, SKMel2, and SKMel23 cells) or RPMI (A375, Hs294T, WM35, and 1205lu cells) supplemented with 10% heat-inactivated FCS, 1% L-glutamine, and 1% penicillinstreptomycin (all from Sigma). B16BL6 melanoma (from Dr. J. Fidler, Cancer Biology, The University of Texas M. D. Anderson Cancer Center, Houston, TX) were cultivated in MEM EBS (AMIMED) supplemented with 5% heat-inactivated FCS, 1% of each L-glutamine, penicillin-streptomycin, sodium pyruvate, nonessential amino acids, and 2% vitamins (stock solutions from AMIMED).
Proliferation and Cell Volume
One day after plating (7 × 10 3 cells/cm 2 ), melanoma cells were exposed to LY294002 (25 μmol/L); wortmannin (500 nmol/L); NVP-BAG956, NVP-BBD130, NVP-BEZ235, and ZSTK474 (1 μmol/L); and rapamycin (100 nmol/L). Compound concentrations were set 2 log units above the IC 50 in vitro to ensure full PI3K inhibition, except for the μmol/L inhibitor LY294002. Cells were trypsinized and counted, and the volume was quantified using a Casy Counter and Analyser (Innovatis AG). To determine the nuclear volume, cells were resuspended in CASYton containing 0.5% Triton X-100, followed by repetitive pipetting (8×), before volume measurements.
Immunoblotting
Total cell lysates were prepared in NP40-based lysis buffer (pH 8 , pSer235/236-S6, pThr32-FOXO1, pSer9-GSK3β, 4E-BP1, and pThr37/46-4E-BP1 were from Cell Signaling Technology; primary antibodies to pMAPK and MAPK were from Sigma; the primary antibody to PKB was a kind gift of E. Hirsch (Turin, Italy); and primary antibodies to cyclin D1 and p27
Kip1 were from Santa Cruz Biotechnology. Secondary antibodies (e.g., horseradish peroxidase-conjugated rabbit anti-mouse IgG and goat anti-rabbit IgG; Sigma) were visualized using enhanced chemiluminescence (Millipore), and fluorescent secondary antibodies (Alexa Fluor 680 or IRDye 800) were detected using the Odyssey IR reader (LICOR).
Cell Cycle and Apoptosis
Melanoma cells were plated (7 × 10 3 /cm 2 ), and PI3K inhibitors (LY294002 at 25 μmol/L; wortmannin at 500 nmol/L; NVP-BAG956, NVP-BBD130, and NVP-BEZ235 at 1 μmol/L) were added 24 h later. After 3 d of exposure to inhibitors, cells were trypsinized and prepared for cell cycle and apoptosis analysis (50) . For cell cycle evaluation, cells were fixed and permeabilized in PBS supplemented with 4% paraformaldehyde/1% bovine serum albumin/0.1% saponin for 30 min at 4°C, and subsequently washed with 1% bovine serum albumin/0.1% saponin in PBS. The pellet was resuspended in 0.1% Triton X-100/0.1% sodium citrate solution (pH 7.4) containing 50 μg/mL propidium iodide and 10 μg/mL DNase-free RNase and incubated for 8 h at 4°C Subsequently, cells were harvested onto glass fiber filters using a cell harvester (FilterMate Harvester, Perkin-Elmer) and incorporated radioactivity was measured using a Perkin-Elmer MicroBeta TriLux.
Cell Cycle Synchronization
Melanoma cells were synchronized by incubation for 14 h with 1 μg/mL nocodazole in the medium described above. Subsequently, the cells were trypsinized, washed with PBS, and plated in the presence or absence of PI3K inhibitors (LY294002 at 25 μmol/L; wortmannin at 500 nmol/L; NVP-BAG956, NVP-BBD130, and NVP-BEZ235 at 1 μmol/L). The cell cycle profile was analyzed as described above.
In vivo Mouse Melanoma Model
B16BL6 mouse melanoma cells were grown until confluent, trypsinized, pelleted, and resuspended (50 × 10 6 /mL) in Hanks buffer supplemented with 10% heat-inactivated FCS. Female C57BL/6 mice (Charles River) were anesthetized NOTE: Effects of PI3K pathway inhibitors on body, spleen, and liver weights, and on glucose levels in the B16 melanoma mouse model. Mice were weighted weekly and sacrificed 13 days after initiation of treatment with the respective inhibitors for autopsy. Whole blood glucose was measured in samples drawn from the vena cava. During the experiment, the mice received water and food ad libitum. Data are presented as mean ± SE, n > 6. *Healthy mice display normal blood glucose of 10 to 15 mmol/L, depending on their feeding status. † P < 0.05 versus vehicle control group. The inhibitors were given for the indicated period, before animals were sacrificed, and primary tumor, cervical lymph node metastases, spleen, liver, femurs, and blood (from the vena cava) were collected for further analysis.
The size of primary tumors at a given time point (=area t ) was determined by digital imaging as described in refs. (51, 52) , and tumor progression was related to the tumor area at day 7 (=area 7days ), and then expressed as percentage of the overall mean tumor size in untreated [vehicle control (VC)] animals (=mean_area_VC 20days ). The depicted values were therefore calculated as follows:
Primary tumor area ð%Þ ¼ ½100 Â area t =area 7d =mean area VC 20d
A fraction of the primary tumors, metastases and liver samples were snap frozen in liquid nitrogen, the rest was fixed in 4% paraformaldehyde for paraffin embedding. Experiments were terminated (here at day 20) for ethical reasons.
Immunohistochemistry
Primary tumors, metastases, and liver tissues were embedded in paraffin using a Spin Tissue Processor (Microm International). Paraffin blocks were cut to 6-μm sections using the Microtome cool-cut HM355S (Microm International). For CD31 (antibody from Bachem AG) staining, tissue slides were deparaffinized using roticlean, and the antigen was unmasked by proteinase K treatment. The staining with the primary antibody was done overnight (antibody dilution 1:50). Subsequently, slides were incubated with a fluorescently labeled secondary antibody and Hoechst 33342 and mounted with crystal solution (Medite). For H&E staining, deparaffinized slides were incubated with hematoxylin solution followed by eosin and mounted with Cytoseal XYL (Medite).
Immune Cell Detection
Cell suspensions of spleen and bone marrow were generated and stained with different cell surface marker antibodies: monoclonal antibodies against CD3 (clone KT3), CD4 (RM4-5), CD8 (53-6.7), B220 (RA3-6B2), CD11b (M1/70), CD11c (HL3), GR1, and TERT were obtained from BD Biosciences PharMingen or eBioscience. The F4/80 antibody was from Serotec. Fluorescence was quantified on a FACSCalibur.
Myr-PKB Transfection and GFP-FOXO Translocation
Cells were plated at 14 × 10 3 /cm 2 , and 24 h later were transfected with 0.1 μg/cm 2 pcDNA3-GFP-FOXO1 and/or pcDNA3-Myr-PKB expression plasmids using JetPEI (Brunschwig Chemie) following the manufacturer's protocol. The following day, cells were exposed to PI3K inhibitors (LY294002 at 25 μmol/L; wortmannin at 500 nmol/L; NVP-BAG956, NVP-BBD130, NVP-BEZ235, and PI103 at 1 μmol/L) or rapamycin (100 nmol/L) for 3 h. HEK293 cells were starved overnight in serum-free DMEM before treatment with the inhibitors.
For immunofluorescence, cells plated on glass coverslips (21 × 10 3 /cm 2 ) were fixed in PBS with 4% paraformaldehyde before nuclei were stained with Hoechst 33342. Coverslips were mounted on microscopy slides in Mowiol (Clariant GMbH). Images were acquired with OpenLab software (Improvision) on an Axiovert 200 M microscope (Zeiss) with a Plan-Achromat 63×/1.4 and an Orca ER II camera (Hamamatsu). 
